Literature DB >> 21883919

Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases.

C Aspord1, D Laurin, M-J Richard, H Vie, L Chaperot, J Plumas.   

Abstract

Virus-associated hematologic malignancies (EBV lymphoproliferative disease) and opportunistic infections (CMV) represent a major cause of hematopoietic stem cell and solid organ transplantation failure. Adoptive transfer of antigen-specific T lymphocytes appears to be a major and successful immunotherapeutic strategy, but improvements are needed to reliably produce high numbers of virus-specific T cells with appropriate requirements for adoptive immunotherapy that would allow extensive clinical use. Since plasmacytoid dendritic cells (pDCs) are crucial in launching antiviral responses, we investigated their capacity to elicit functional antiviral T-cell responses for adoptive cellular immunotherapy using a unique pDC line and antigens derived from Influenza, CMV and EBV viruses. Stimulation of peripheral blood mononuclear cells from HLA-A*0201(+) donors by HLA-A0201 matched pDCs pulsed with viral-derived peptides triggered high levels of multi-specific and functional cytotoxic T-cell responses (up to 99% tetramer(+) CD8 T cells) in vitro. Furthermore, the central/effector memory cytotoxic T cells elicited by the pDCs strongly display antiviral activity upon adoptive transfer into a humanized mouse model that mimics a virus-induced malignancy. We provide a simple and potent method to generate virus-specific CTL with the required properties for adoptive cellular immunotherapy of post-transplant diseases. ©Copyright 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21883919     DOI: 10.1111/j.1600-6143.2011.03722.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  8 in total

Review 1.  New generation humanized mice for virus research: comparative aspects and future prospects.

Authors:  Ramesh Akkina
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

2.  POTN: A Human Leukocyte Antigen-A2 Immunogenic Peptides Screening Model and Its Applications in Tumor Antigens Prediction.

Authors:  Qingqing Meng; Yahong Wu; Xinghua Sui; Jingjie Meng; Tingting Wang; Yan Lin; Zhiwei Wang; Xiuman Zhou; Yuanming Qi; Jiangfeng Du; Yanfeng Gao
Journal:  Front Immunol       Date:  2020-10-07       Impact factor: 7.561

3.  Factors associated with cytomegalovirus reactivation following allogeneic hematopoietic stem cell transplantation: human leukocyte antigens might be among the risk factors.

Authors:  Kadir Acar; Sahika Zeynep Akı; Zübeyde Nur Ozkurt; Gülendam Bozdayı; Seyyal Rota; Gülsan Türköz Sucak
Journal:  Turk J Haematol       Date:  2014-09-05       Impact factor: 1.831

4.  An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial.

Authors:  Julie Charles; Laurence Chaperot; Dalil Hannani; Juliana Bruder Costa; Isabelle Templier; Sabiha Trabelsi; Hugo Gil; Anaick Moisan; Virginie Persoons; Harald Hegelhofer; Edith Schir; Jean-Louis Quesada; Christophe Mendoza; Caroline Aspord; Olivier Manches; Pierre G Coulie; Amir Khammari; Brigitte Dreno; Marie-Thérèse Leccia; Joel Plumas
Journal:  Oncoimmunology       Date:  2020-04-12       Impact factor: 8.110

Review 5.  Herpesvirus Respiratory Infections in Immunocompromised Patients: Epidemiology, Management, and Outcomes.

Authors:  Gail E Reid; Joseph P Lynch; Samuel Weigt; David Sayah; John A Belperio; Shellee A Grim; Nina M Clark
Journal:  Semin Respir Crit Care Med       Date:  2016-08-03       Impact factor: 3.119

6.  Engineering a Human Plasmacytoid Dendritic Cell-Based Vaccine to Prime and Expand Multispecific Viral and Tumor Antigen-Specific T-Cells.

Authors:  Kevin Lenogue; Alexandre Walencik; Karine Laulagnier; Jean-Paul Molens; Houssem Benlalam; Brigitte Dreno; Pierre Coulie; Martin Pule; Laurence Chaperot; Joël Plumas
Journal:  Vaccines (Basel)       Date:  2021-02-10

Review 7.  Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy.

Authors:  Hong-Li Wang; Zhi-Gang Wang; Shu-Lin Liu
Journal:  Molecules       Date:  2022-08-31       Impact factor: 4.927

Review 8.  How to approach and treat viral infections in ICU patients.

Authors:  Theodoros Kelesidis; Ioannis Mastoris; Aliki Metsini; Sotirios Tsiodras
Journal:  BMC Infect Dis       Date:  2014-11-28       Impact factor: 3.667

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.